NewAmsterdam Pharma Company N.V.
Price Action
Technical Summary
CONSOLIDATINGNewAmsterdam Pharma Company N.V. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 74), indicating performance broadly in line with the market. Earnings contraction of 18% provides fundamental context to the price action. Investors should exercise caution due to high volatility (57% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $32.84 | +7.91% | ABOVE |
| 50 SMA | $32.23 | +9.95% | ABOVE |
| 100 SMA | $33.02 | +7.32% | ABOVE |
| 150 SMA | $34.41 | +2.99% | ABOVE |
| 200 SMA | $32.31 | +9.68% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is NAMS in an uptrend right now?
NAMS has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is NAMS overbought or oversold?
NAMS's RSI (14) is 61. The stock is in neutral territory, neither overbought nor oversold.
Is NAMS outperforming the market?
NAMS has a Relative Strength (RS) Rating of 74 out of 99. NAMS is performing about average compared to the market.
Where is NAMS in its 52-week range?
NAMS is trading at $35.44, which is 84% of its 52-week high ($42.20) and 73% above its 52-week low ($16.79).
How volatile is NAMS?
NAMS has a Beta of 1.44 and 52-week volatility of 57%. It's more volatile than the S&P 500 - expect bigger swings.